The Asia-Pacific Journal of Ophthalmology

Asia-Pacific Journal of Ophthalmology:

Issue 1, January/February 2018 Review Article

Management of Retinopathy of Prematurity—Use of Anti-VEGF Therapy

Tran, Kimberly D.; Cernichiaro-Espinosa, Linda A.; Berrocal, Audina M.

Author Information

From the *Department of Ophthalmology and †Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.Received for publication October 16, 2017; accepted November 27, 2017.A.M.B. is a consultant for Alcon, Inc (CA); Dutch Ophthalmic Research Center International BV (DORC, The Netherlands); and Visunex Medical Systems (CA).

Reprints: Audina M. Berrocal MD, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136. E-mail: E-mail:


Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide. Although laser photocoagulation re-mains the gold standard for treating threshold and prethreshold disease (type 1 ROP), the off-label use of anti‒vascular endothelial growth factor (anti-VEGF) therapy to treat ROP is increasing. Benefits include acute regression of ROP, growth of retinal vasculature beyond the demarcation line, lesser degree of myopia and peripheral visual field loss, and avoidance of sedation and intubation required for laser. However, controversies regarding anti-VEGF in this vulnerable population persist including choice of anti-VEGF agent, dosing, systemic absorption, safety, and late recurrence. This review updates recent evidence regarding the use of anti-VEGF therapy in the management of ROP.

Full Text

View PDF Online

Download PDF

APJO Express

More About APAO

  • 1
  • 2
  • 3
  • 4
< >
All Rights Reserved © Asia-Pacific Academy of Ophthalmology